TO · TH.TO
Theratechnologies Inc.
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Montreal, QC H3A 1T8
- Website
- theratech.com
Price · as of 2024-11-30
$4.47
Market cap 205.53M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $95.00 | +2,025.28% |
| Intrinsic Value(DCF) | $0.92 | -79.42% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $23.12 | $69.11 | $332.49 | $2.20 | $18.90 |
| 2011 | $9.16 | $387.06 | $3.82 | $0.00 | $17.10 |
| 2012 | $2.20 | $39.14 | $0.00 | $0.00 | $0.00 |
| 2013 | $1.92 | $45.60 | $0.03 | $0.00 | $3.30 |
| 2014 | $2.24 | $37.29 | $0.00 | $0.00 | $1.80 |
| 2015 | $6.56 | $107.89 | $0.19 | $0.50 | $7.30 |
| 2016 | $14.32 | $51.19 | $0.00 | $0.50 | $0.20 |
| 2017 | $28.00 | $201.55 | $0.33 | $0.00 | $0.00 |
| 2018 | $31.76 | $63.60 | $20.17 | $0.20 | $0.00 |
| 2019 | $15.20 | $65.00 | $58.58 | $0.00 | $0.00 |
| 2020 | $13.04 | $35.53 | $26.46 | $0.00 | $0.00 |
| 2021 | $15.88 | $42.02 | $2.01 | $0.00 | $0.00 |
| 2022 | $4.76 | $36.90 | $0.36 | $0.00 | $0.00 |
| 2023 | $2.19 | $41.23 | $0.00 | $0.00 | $0.00 |
| 2024 | $2.30 | $67.98 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Theratechnologies Inc.'s (TH.TO) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $95.00
- Current price
- $4.47
- AI upside
- +2,025.28%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$0.92
-79.42% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
About Theratechnologies Inc.
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
- CEO
- Paul Lévesque
- Employees
- 103
- Beta
- 0.81
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.92 ÷ $4.47) − 1 = -79.42% (DCF, example).